Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.

Get Updates in Your Inbox

Sign Up.  Stay Informed.

The Conversation

LAST WORD: Treatments for Hereditary Angioedema

LAST WORD: Treatments for Hereditary Angioedema

On August 24, 2021, ICER released a revised version of a final evidence report from 2018 evaluating the clinical and cost effectiveness of three emerging treatments for hereditary angioedema. Unfortunately, while ICER tried to update its analysis -- supposedly to...

read more
LAST WORD: Treatments for Atopic Dermatitis

LAST WORD: Treatments for Atopic Dermatitis

On August 17, 2021, ICER issued a Final Evidence Report on the clinical and cost-effectiveness of new treatments for atopic dermatitis (more commonly referred to as eczema). After following its typical process for gathering and reviewing data, ICER concluded that the...

read more